Search Results - "HOLMAN, Laura L."

Symptom trajectories over time by cannabis use status among patients undergoing cancer treatment by Niznik, Taylor, Boozary, Laili K., Chen, Meng, Cohn, Amy M., Ulahannan, Susanna V., Henson, Christina E., Alexander, Adam C., Moore, Kathleen N., Holman, Laura L., Queimado, Lurdes, Kendzor, Darla E.

“…Adults with cancer may perceive cannabis as beneficial for managing their cancer-related symptoms, but the evidence supporting its medical use is varied and…”
Get full text

Sentinel Lymph Node Evaluation in Women with Cervical Cancer by Holman, Laura L., MD, Levenback, Charles F., MD, Frumovitz, Michael, MD, MPH

“…Abstract Lymph node status is the most important prognosticator of survival in women with early stage cervical cancer. Thus many patients with cervical cancer…”
Get full text

Factors prognostic of survival in advanced-stage uterine serous carcinoma by Holman, Laura L, Pal, Navdeep, Iglesias, David A, Soliman, Pamela T, Balakrishnan, Nyla, Klopp, Ann, Broaddus, Russell R, Fleming, Nicole D, Munsell, Mark F, Lu, Karen H, Westin, Shannon N

“…Abstract Objectives The study objective was to analyze the impact of prognostic factors, including treatment modality, on outcome in patients with…”
Get full text

Risk perception, worry, and test acceptance in average-risk women who undergo ovarian cancer screening by Holman, Laura L., MD, Lu, Karen H., MD, Bast, Robert C., MD, Hernandez, Mary A., RN, MSN, Bodurka, Diane C., MD, Skates, Steven, PhD, Sun, Charlotte C., DrPH, MPH

“…Objective We evaluated baseline knowledge of ovarian cancer risk and perceptions toward ovarian cancer screening (OCS) by initiating the normal risk ovarian…”
Get full text

Laparoscopic Supracervical Hysterectomy With Morcellation: Should It Stay or Should It Go? by Brown, Jubilee, MD, Taylor, Kristal, MD, Ramirez, Pedro T., MD, Sun, Charlotte, DrPH, Holman, Laura L., MD, Cone, S. Mark, MD, Irwin, John, MD, Frumovitz, Michael, MD, MPH

“…Abstract Study Objective To establish the risk of unidentified neoplasia and subsequent adverse outcomes of laparoscopic supracervical hysterectomy (SCH) with…”
Get full text

Recurrence Rates in Patients With Cervical Cancer Treated With Abdominal Versus Minimally Invasive Radical Hysterectomy: A Multi-Institutional Retrospective Review Study by Uppal, Shitanshu, Gehrig, Paola A, Peng, Katherine, Bixel, Kristin L, Matsuo, Koji, Vetter, Monica H, Davidson, Brittany A, Cisa, M Paige, Lees, Brittany F, Brunette, Laurie L, Tucker, Katherine, Stuart Staley, Allison, Gotlieb, Walter H, Holloway, Robert W, Essel, Kathleen G, Holman, Laura L, Goldfeld, Ester, Olawaiye, Alexander, Rose, Stephen L

“…To compare the disease-free survival (DFS) between open and minimally invasive radical hysterectomies (RH) performed in academic medical institutions…”
Get full text

Genetic Risk and Gynecologic Cancers by Holman, Laura L., MD, Lu, Karen H., MD

“…Hereditary cancer syndromes are responsible for 5% of endometrial cancers and 10% of ovarian cancers. Hereditary breast and ovarian cancer syndrome and Lynch…”
Get full text

An Overview of Immune Checkpoint Inhibitors in Gynecologic Cancers by Castellano, Tara, Moore, Kathleen N., Holman, Laura L.

“…The goal of this study was to compile a review of topics pertinent to the use of immune checkpoint inhibitors in gynecologic malignancies, including foundation…”
Get full text

A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study by Slomovitz, Brian M., Filiaci, Virginia L., Walker, Joan L., Taub, Michael C., Finkelstein, Karen A., Moroney, John W., Fleury, Aimee C., Muller, Carolyn Y., Holman, Laura L., Copeland, Larry J., Miller, David S., Coleman, Robert L.

“…Blocking the PI3K/AKT/mTOR pathway decreases resistance to hormonal therapy in endometrial carcinoma (EC). In this study, the aim was to assess the efficacy…”
Get full text

Acceptability of prophylactic salpingectomy with delayed oophorectomy as risk-reducing surgery among BRCA mutation carriers by Holman, Laura L, Friedman, Sue, Daniels, Molly S, Sun, Charlotte C, Lu, Karen H

“…Abstract Objective Given the emerging evidence for the fimbria as the site of origin for many serous carcinomas in BRCA mutation carriers, consideration is…”
Get full text

Cannabis use among adults undergoing cancer treatment by Azizoddin, Desiree R, Cohn, Amy M, Ulahannan, Susanna V, Henson, Christina E, Alexander, Adam C, Moore, Kathleen N, Holman, Laura L, Boozary, Laili Kharazi, Sifat, Munjireen S, Kendzor, Darla E

“…Little is known about the risks and benefits of cannabis use in the context of cancer care. This study characterized the prevalence, reasons for use, and…”
Get full text

Bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction: A pilot study in women with BRCA1/2 mutations by Nebgen, Denise R., Hurteau, Jean, Holman, Laura L., Bradford, Andrea, Munsell, Mark F., Soletsky, Beth R., Sun, Charlotte C., Chisholm, Gary B., Lu, Karen H.

“…Risk-reducing salpingo-oophorectomy (RRSO) reduces ovarian cancer risk in BRCA1/2 mutation carriers, but the adverse effects of the associated early-onset…”
Get full text

Beyond Sedlis—A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis by Levinson, Kimberly, Beavis, Anna L., Purdy, Christopher, Rositch, Anne F., Viswanathan, Akila, Wolfson, Aaron H., Kelly, Michael G., Tewari, Krishnansu S., McNally, Leah, Guntupalli, Saketh R., Ragab, Omar, Lee, Yi-Chun, Miller, David S., Huh, Warner K., Wilkinson, Kelly J., Spirtos, Nicola M., Van Le, Linda, Casablanca, Yovanni, Holman, Laura L., Waggoner, Steven E., Fader, Amanda N.

“…The Sedlis criteria define risk factors for recurrence warranting post-hysterectomy radiation for early-stage cervical cancer; however, these factors were…”
Get full text

Incorporation of whole pelvic radiation into treatment of stage IVB cervical cancer: A novel treatment strategy by Perkins, Victoria, Moore, Kathleen, Vesely, Sara, Matsuo, Koji, Mostofizadeh, Sayedamin, Sims, Travis T., Lea, Jayanthi, Barnes, Dominique, Chen, Sixia, Carlson, Matthew, Roman, Lynda, Monk, Bradley J., Holman, Laura L.

“…Chemotherapy is the standard treatment in stage IVB cervical cancer (CC). However, given that many women have a significant pelvic disease burden, whole pelvic…”
Get full text

Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14 by Brown, Jubilee, Miller, Austin, Holman, Laura L., Backes, Floor, Nagel, Christa, Bender, David, Miller, David S., Powell, Matthew A., Westin, Shannon N., Bonebrake, Albert, Muller, Carolyn Y., Secord, Angeles Alvarez, Crane, Erin, Schorge, John, Tew, William P., Sood, Anil K., Bookman, Michael A., Aghajanian, Carol, Gershenson, David M.

“…To assess the efficacy and toxicity of paclitaxel and carboplatin (PC) compared to bleomycin, etoposide, and cisplatin (BEP) for treatment of newly diagnosed…”
Get full text

Trends and outcomes of women with synchronous endometrial and ovarian cancer by Matsuo, Koji, Machida, Hiroko, Blake, Erin A, Holman, Laura L, Rimel, Bobbie J, Roman, Lynda D, Wright, Jason D

“…This retrospective observational study examined trends, characteristics, and survival of women with synchronous endometrial and ovarian cancer (SEOC) in the…”
Get full text

Comprehensive genomic profiling of recurrent endometrial cancer: Implications for selection of systemic therapy by Prendergast, Emily N, Holman, Laura L, Liu, Annie Y, Lai, Tiffany S, Campos, Maira P, Fahey, Jacquline N, Wang, Xiaoyan, Abdelaal, Nabilah, Rao, Jian Yu, Elvin, Julia A, Moore, Kathleen M, Konecny, Gottfried E, Cohen, Joshua G

“…AbstractObjectivesTo assess whether comprehensive genomic profiling (CGP) in the setting of routine clinical care allows molecular classification of recurrent…”
Get full text

Association between Serum Biomarkers with Postoperative Complications and Delay of Adjuvant Chemotherapy Initiation in Ovarian Cancer Patients Undergoing Primary Cytoreductive Surgery: A Pilot Study by Ade, Carl J, Dockery, Lauren, Walter, Adam C, Benbrook, Doris M, Vesely, Sara K, Hammond, Stephen T, Moore, Kathleen N, Holman, Laura L

“…This study sought to describe and relate the factors associated with complications and delays in adjuvant chemotherapy in patients with ovarian cancer treated…”
Get full text

Multiple Luteinized Follicle Cysts of the Ovary in a Patient With a Pituitary Adenoma: Report of a Case and Review of the Literature by Lebok, Patrick, Zuna, Rosemary E, Holman, Laura L, Young, Robert H

“…The case of a 36-yr-old woman with a pituitary adenoma who was found to have bilateral ovarian masses is reported. The right ovary was removed, measured 15 cm…”
Get full text

A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response by Duska, Linda R, Filiaci, Virginia L, Walker, Joan L, Holman, Laura L, Hill, Emily K, Moore, Richard G, Ring, Kari L, Pearl, Michael L, Muller, Carolyn Y, Kushnir, Christina L, Lankes, Heather A, Samuelson, Megan I, Carrick, Kelley S, Rajan, Anand, Rodgers, William H, Kohn, Elise C, Piekarz, Richard, Leslie, Kimberly K

“…This surgical window of opportunity (window) study assessed the short-term effect of medroxyprogesterone acetate (MPA) alone versus MPA plus the histone…”
Get full text